nach oben

Diabetologia

Erschienen in:

01.07.2007 | Metaanalysis

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

verfasst von: E. Friberg, N. Orsini, C. S. Mantzoros, A. Wolk

Erschienen in: Diabetologia | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Diabetes has been associated with a statistically significantly increased risk of endometrial cancer in most, but not all studies. To provide a quantitative assessment of the association between diabetes and risk of endometrial cancer, we conducted a meta-analysis of case-control studies and cohort studies.

Subjects and methods

We identified studies by a literature search of PubMed and Embase through to January 2007 and by searching the reference lists of relevant articles. Summary relative risks (RRs) with 95% CIs were calculated using random-effects model.

Results

The analysis of diabetes (largely type 2) and endometrial cancer is based on 16 studies (three cohort and 13 case-control studies), including 96,003 participants and 7,596 cases of endometrial cancer. Twelve of the studies showed a statistically significantly increased risk and four a non-significant increased risk of endometrial cancer. In our meta-analysis we found that diabetes was statistically significantly associated with an increased risk of endometrial cancer (summary RR 2.10, 95% CI 1.75–2.53). The risk estimates were somewhat stronger among case-control (RR 2.22, 95% CI 1.80–2.74) than among cohort studies (RR 1.62, 95% CI 1.21–2.16), stronger among studies adjusting only for age (RR 2.74, 95% CI 1.87–4.00) compared with multivariate adjustment (RR 1.92, 95% CI 1.58–2.33) and slightly lower in studies performed in the USA than in those performed Europe. The analysis of type 1 diabetes and endometrial cancer was based on three studies and found a statistically significant positive association (summary RR 3.15, 95%CI 1.07–9.29).

Conclusions/interpretation

Results from the meta-analysis support a relationship between diabetes and increased risk of endometrial cancer.

WHO website: http://www.who.int/diabetes/facts/en/, last accessed 4 May 2006

Polednak AP (2003) Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect Prev 27:415–421CrossRefPubMed

Bray F, Dos Santos Silva I, Moller H, Weiderpass E (2005) Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 14:1132–1142CrossRefPubMed

Kissebah AH, Vydelingum N, Murray R et al (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254–260PubMed

Bjorntorp P (1991) Metabolic implications of body fat distribution. Diabetes Care 14:1132–1143CrossRefPubMed

International Agency for Research on Cancer (2002) Weight control and physical activity. IARC, Lyon

Schouten LJ, Goldbohm RA, van den Brandt PA (2004) Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands cohort study. J Natl Cancer Inst 96:1635–1638PubMedCrossRef

Modesitt SC, van Nagell JR Jr (2005) The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv 60:683–692CrossRefPubMed

Friberg E, Mantzoros CS, Wolk A (2007) Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 16:276–280CrossRefPubMed

10.

Weiss JM, Saltzman BS, Doherty JA et al (2006) Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol 164:56–62CrossRefPubMed

11.

Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA (2000) Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 11:185–192CrossRefPubMed

12.

Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG et al (2000) Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 11:707–711CrossRefPubMed

13.

Parazzini F, La Vecchia C, Negri E et al (1999) Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer 81:539–542CrossRefPubMed

14.

Shoff SM, Newcomb PA (1998) Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 148:234–240PubMed

15.

Maatela J, Aromaa A, Salmi T, Pohja M, Vuento M, Gronroos M (1994) The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol Suppl 208:20–24PubMed

16.

Inoue M, Okayama A, Fujita M, Enomoto T, Tanizawa O, Ueshima H (1994) A case-control study on risk factors for uterine endometrial cancer in Japan. Jpn J Cancer Res 85:346–350PubMed

17.

Brinton LA, Berman ML, Mortel R et al (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167:1317–1325PubMed

18.

Lawrence C, Tessaro I, Durgerian S, Caputo T, Richart RM, Greenwald P (1989) Advanced-stage endometrial cancer: contributions of estrogen use, smoking, and other risk factors. Gynecol Oncol 32:41–45CrossRefPubMed

19.

Zemla B, Guminski S, Banasik R (1986) Study of risk factors in invasive cancer of the corpus uteri. Neoplasma 33:621–629PubMed

20.

O’Mara BA, Byers T, Schoenfeld E (1985) Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 38:435–441CrossRefPubMed

21.

Folsom AR, Anderson KE, Sweeney C, Jacobs DR Jr (2004) Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol 94:740–745CrossRefPubMed

22.

Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S (1990) Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 162:148–154PubMed

23.

Kelsey JL, LiVolsi VA, Holford TR et al (1982) A case-control study of cancer of the endometrium. Am J Epidemiol 116:333–342PubMed

24.

Anderson KE, Anderson E, Mink PJ et al (2001) Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 10:611–616PubMed

25.

Terry P, Baron JA, Weiderpass E, Yuen J, Lichtenstein P, Nyren O (1999) Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer 82:38–42CrossRefPubMed

26.

Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167CrossRefPubMed

27.

Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE (2001) Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control 12:829–835CrossRefPubMed

28.

Parslov M, Lidegaard O, Klintorp S et al (2000) Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 182:23–29CrossRefPubMed

29.

Hagen A, Morack G, Grulich D (1995) Evaluation of epidemiologic risk factors for endometrial carcinoma based on a case-control study. Zentralbl Gynakol 117:368–374 [in German]PubMed

30.

Feldman S, Cook EF, Harlow BL, Berkowitz RS (1995) Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 56:376–381CrossRefPubMed

31.

La Vecchia C, Negri E, Franceschi S, D’Avanzo B, Boyle P (1994) A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70:950–953PubMed

32.

Geraci P, Mancuso A, Maggio S, Dardanoni G (1988) Risk factors of endometrial cancer in Palermo. Clin Exp Obstet Gynecol 15:129–133PubMed

33.

Elwood JM, Cole P, Rothman KJ, Kaplan SD (1977) Epidemiology of endometrial cancer. J Natl Cancer Inst 59:1055–1060PubMed

34.

Swerdlow AJ, Laing SP, Qiao Z et al (2005) Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 92:2070–2075CrossRefPubMed

35.

Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed

36.

Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO (1997) Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 71:360–363CrossRefPubMed

37.

Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365CrossRefPubMed

38.

Ragozzino M, Melton LJ 3rd, Chu CP, Palumbo PJ (1982) Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 35:13–19CrossRefPubMed

39.

Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26:1047–1051CrossRefPubMed

40.

Kessler II (1970) Cancer mortality among diabetics. J Natl Cancer Inst 44:673–686PubMed

41.

Adami HO, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314CrossRefPubMed

42.

Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1–30PubMed

43.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

44.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed

45.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed

46.

Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ, London

47.

Nagamani M, Stuart CA (1998) Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol 179:6–12CrossRefPubMed

48.

Lukanova A, Zeleniuch-Jacquotte A, Lundin E et al (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108:262–268CrossRefPubMed

49.

Kazer RR (1995) Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int J Cancer 62:403–406CrossRefPubMed

50.

Nestler JE, Powers LP, Matt DW et al (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83–89PubMedCrossRef

51.

Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502–519CrossRefPubMed

52.

Ferenczy A, Bertrand G, Gelfand MM (1979) Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 133:859–867PubMed

53.

Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57:205–212PubMed

54.

Irwin JC, de las Fuentes L, Dsupin BA, Giudice LC (1993) Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion. Regul Pept 48:165–177CrossRefPubMed

55.

Murphy LJ (1994) Growth factors and steroid hormone action in endometrial cancer. J Steroid Biochem Mol Biol 48:419–423CrossRefPubMed

56.

Corocleanu M (1993) Hypothesis for endometrial carcinoma carcinogenesis. Preventive prospects. Clin Exp Obstet Gynecol 20:254–258PubMed

57.

Thiet MP, Osathanondh R, Yeh J (1994) Localization and timing of appearance of insulin, insulin-like growth factor-I, and their receptors in the human fetal mullerian tract. Am J Obstet Gynecol 170:152–156PubMed

58.

Ordener C, Cypriani B, Vuillermoz C, Adessi GL (1993) Epidermal growth factor and insulin induce the proliferation of guinea pig endometrial stromal cells in serum-free culture, whereas estradiol and progesterone do not. Biol Reprod 49:1032–1044CrossRefPubMed

59.

Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R (2003) Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer 89:1697–1704CrossRefPubMed

60.

Steffes MW, Gross MD, Schreiner PJ et al (2004) Serum adiponectin in young adults-interactions with central adiposity, circulating levels of glucose, and insulin resistance: the CARDIA study. Ann Epidemiol 14:492–498CrossRefPubMed

61.

Dal Maso L, Augustin LS, Karalis A et al (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163CrossRef

Titel: Diabetes mellitus and risk of endometrial cancer: a meta-analysis
verfasst von: E. Friberg
N. Orsini
C. S. Mantzoros
A. Wolk
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 7/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0681-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Subjects and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Comment on: Davidson MB (2007) The dilemma of self-monitoring of blood glucose. Diabetologia 50:497–499

Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto–Kakizaki rat model of type 2 diabetes

Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study

Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction

Response to comment on: Davidson MB (2007) The dilemma of self-monitoring of blood glucose. Diabetologia 50:497–499